Birgitta Versluijs

140 Results TABLE 1. Patient characteristics Allo-LS andTotal Cohort Allo-LS N=53 Total Cohort N=361 Pearsons chi-square Age, median [yr] (range) 6.88 (0.3-18.8) 7.4 (0.2-22.7) NS Gender  Male  Female 26 (49%) 27 (51%) 216 (59%) 145 (41%) NS Primary disease  Malignant  Bone marrow failure syndrome  Inborn error of metabolism  Primary Immune deficiency 22 (42%) 4 (7%) 16 (30%) 11 (21%) 188 (52%) 44 (12%) 62 (17%) 67 (18%) *0.04 Donor  Related  Unrelated 13 (25%) 40 (75%) 89 (25%) 272 (75%) NS Stem cell source  Bone marrow  Cord Blood  PBSC 23 (43%) 29 (55%) 1 (2%) 151 (42%) 199 (55%) 11 (3%) NS Conditioning regimen  Myeloablative Busulfan based  RIC, no/lower dose Busulfan  Myeloablative TBI based 46 (87%) 4 (7%) 3 (6%) 245 (68%) 74 (20%) 42 (11%) *0.02 Serotherapy  Yes  No 35 (66%) 18 (34%) 251 (70%) 110 (30%) NS HLA matching  Matched Bone marrow (10/10)  Mismatched Bone marrow  Matched Cord blood (6/6)  Mismatched Cord blood (5/6)  Mismatched Cord blood (4/6) 20 (38%) 4 (7%) 7 (13%) 17 (32%) 5 (9%) 142 (39%) 25 (7%) 71(20%) 92 (25%) 31(9%) NS Allo-LS, Alloimmune mediated lung syndrome; PBSC, Peripheral Blood Stem Cells; TBI, total body irradiation; RIC, reduced intensity conditioning; HLA, Human Leukocyte Anti- gen. 8